Head to Head Comparison: Biolase (BIOL) vs. Its Peers
Biolase (NASDAQ: BIOL) is one of 82 publicly-traded companies in the “Advanced Medical Equipment & Technology” industry, but how does it compare to its rivals? We will compare Biolase to related companies based on the strength of its profitability, earnings, analyst recommendations, valuation, dividends, risk and institutional ownership.
Institutional and Insider Ownership
37.3% of Biolase shares are owned by institutional investors. Comparatively, 53.2% of shares of all “Advanced Medical Equipment & Technology” companies are owned by institutional investors. 7.1% of Biolase shares are owned by insiders. Comparatively, 17.0% of shares of all “Advanced Medical Equipment & Technology” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
This is a summary of recent ratings for Biolase and its rivals, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Biolase presently has a consensus target price of $2.50, suggesting a potential upside of 314.73%. As a group, “Advanced Medical Equipment & Technology” companies have a potential downside of 17.88%. Given Biolase’s stronger consensus rating and higher probable upside, analysts clearly believe Biolase is more favorable than its rivals.
Valuation and Earnings
This table compares Biolase and its rivals gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Biolase||$50.48 million||-$14.68 million||-1.88|
|Biolase Competitors||$2.02 billion||$430.74 million||-70.77|
Biolase’s rivals have higher revenue and earnings than Biolase. Biolase is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Risk and Volatility
Biolase has a beta of 2.26, meaning that its share price is 126% more volatile than the S&P 500. Comparatively, Biolase’s rivals have a beta of 0.89, meaning that their average share price is 11% less volatile than the S&P 500.
This table compares Biolase and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Biolase rivals beat Biolase on 7 of the 12 factors compared.
BIOLASE, Inc. (BIOLASE) is a medical device company that develops, manufactures, markets and sells laser systems in dentistry and medicine. The Company markets, sells, and distributes dental imaging equipment, including cone beam digital x-rays and computer-aided design (CAD)/computer-aided manufacturing (CAM) intra-oral scanners, in-office, chair-side milling machines and three-dimensional (3-D) printers. It offers two categories of laser system products: WaterLase (all-tissue) systems and Diode (soft tissue) systems. Its brand, WaterLase, uses a combination of water and laser energy to perform procedures performed using drills, scalpels, and other traditional dental instruments for cutting soft and hard tissue. It also offers its Diode laser systems to perform soft tissue, pain therapy, and cosmetic procedures, including teeth whitening. Its Waterlase and Diode systems use disposable laser tips of differing sizes and shapes depending on the procedures being performed.
Receive News & Ratings for Biolase Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biolase Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.